Company: VERA
Filing Date: 2025-12-10
Form Type: 424B5
Source: 0001193125-25-314244
Chunk: 10

Company: Vera Therapeutics, Inc.
Filing Date: 2025-12-10
Form: 424B5
Chunk 10
---
 supplement. See “Where you can find more information.”

S-7

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the
relevant subject. These statements are based on information available to us as of the date of this prospectus supplement, and accompanying prospectus or the documents incorporated by reference in this prospectus supplement, as applicable, and while
we believe such information provides a reasonable basis for these statements, and our management is responsible for the accuracy of such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we
have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely on these statements.

S-8

Use of proceeds

We estimate that the net proceeds from our issuance and sale of shares of our Class A common stock in this offering will be approximately $244.5 million, or
approximately $281.3 million if the underwriters exercise their option to purchase additional shares of our Class A common stock in full, in each case, after deducting underwriting discounts and commissions and estimated offering expenses
payable by us.

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the potential
commercial launch of atacicept in IgAN, which we anticipate would occur in 2026, if approved, and the development of new clinical indications for atacicept, and the remainder for general corporate purposes, including working capital, operating
expenses and capital expenditures.

Based on our current operating plan and our expectations regarding the timing of review and potential approval by the FDA of our
BLA for the use of atacicept in IgAN, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents and the funds available to us under our Loan and Security Agreement with Oxford, will be sufficient to
fund our projected operating requirements through potential commercial launch of atacicept in IgAN, if approved.

We may also use a portion of the net proceeds to
acquire or invest in businesses and products that are complementary to our own, although we have no current plans, commitments or agreements with respect to any acquisitions as of the date of this prospectus supplement. Pending the use of net
proceeds, we intend to invest the net proceeds in short-term, investment-grade, interest bearing instruments in accordance with our investment policy.

The